Kura Oncology, Inc.

As of June 30, 2026, Kura Oncology, Inc. carries a market capitalization of 848.62M, placing it among publicly traded companies globally. Its enterprise value stands at 415.72M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Kura Oncology, Inc.'s next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Kura Oncology, Inc. has 88.95M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 12.46, and the price-to-book ratio stands at 20.02.

These figures are as of June 30, 2026. The EV/Sales ratio of 6.15 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 415.72M versus a market cap of 848.62M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Kura Oncology, Inc. maintains a current ratio of 4.73, meaning it holds 4.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 50.49, indicating elevated leverage, while an interest coverage ratio of -223.10 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Kura Oncology, Inc. posted a negative return on equity (ROE) of -167.71, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -46.73, reflecting losses generated across the asset base. The company generates approximately 278,168.90 in revenue per employee across its workforce of 243.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Kura Oncology, Inc. recorded 73,525.20 in income tax expense. The company reported a pretax loss of -259.69M and -259.77M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Kura Oncology, Inc.'s stock has gained approximately 11.33% over the past 52 weeks. The 50-day moving average sits at 9.97, while the 200-day moving average is 8.51.

Over the twelve months ended June 30, 2026, Kura Oncology, Inc. generated 67.60M in revenue and converted that into -259.77M in net income, yielding earnings per share of -2.94. EBITDA reached -277.29M, while operating income came in at -278.42M.

As of June 30, 2026, Kura Oncology, Inc. holds 454.30M in cash and equivalents against 21.41M in total debt, resulting in a net debt position of -52.91M. Total book value stands at 42.39M, with working capital of 386.22M providing operational flexibility.

Kura Oncology, Inc. produced -97.82M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -4.96M in capital expenditures, free cash flow totaled -102.79M - equivalent to -1.16 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -411.90 and net profit margin of -384.30 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -12.20: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.28, meaning Kura Oncology, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Kura Oncology, Inc. has an Altman Z-Score of -2.81, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.